Enabling High Throughput AI-Designed AAV Libraries To Accelerate Gene Therapy Development

Success in gene therapy relies on the ability to safely and precisely deliver a genetic payload to the intended target cells. To enable the potential of gene therapy, novel, optimized capsids are needed. This presentation describes a novel approach that combines next-gen library synthesis, next-gen sequencing, artificial intelligence, and novel fixed bed bioreactor technology to accelerate the production of improved indication specific AAV capsids, to deliver therapeutic transgenes. Chris Reardon, Lead Process Design Engineer, AAV Production at Dyno Therapeutics shares their strategy for efficiently scaling up high throughput AAV library production, including results from recent studies using the Corning® Ascent™ fixed bed bioreactor technology.